key: cord-0746984-2056vtld
authors: Latosinska, Agnieszka; Siwy, Justyna; Cherney, David Z.; Perkins, Bruce A.; Mischak, Harald; Beige, Joachim
title: SGLT2‐Inhibition reverts urinary peptide changes associated with severe COVID‐19: An in‐silico proof‐of‐principle of proteomics‐based drug repurposing
date: 2021-09-15
journal: Proteomics
DOI: 10.1002/pmic.202100160
sha: 2107462c7620173507e198a825243f710cc051c8
doc_id: 746984
cord_uid: 2056vtld

Severe COVID‐19 is reflected by significant changes in urine peptides. Based on this observation, a clinical test predicting COVID‐19 severity, CoV50, was developed and registered as in vitro diagnostic in Germany. We have hypothesized that molecular changes displayed by CoV50, likely reflective of endothelial damage, may be reversed by specific drugs. Such an impact by a drug could indicate potential benefits in the context of COVID‐19. To test this hypothesis, urinary peptide data from patients without COVID‐19 prior to and after drug treatment were collected from the human urinary proteome database. The drugs chosen were selected based on availability of sufficient number of participants in the dataset (n > 20) and potential value of drug therapies in the treatment of COVID‐19 based on reports in the literature. In these participants without COVID‐19, spironolactone did not demonstrate a significant impact on CoV50 scoring. Empagliflozin treatment resulted in a significant change in CoV50 scoring, indicative of a potential therapeutic benefit. The study serves as a proof‐of‐principle for a drug repurposing approach based on human urinary peptide signatures. The results support the initiation of a randomized control trial testing a potential positive effect of empagliflozin for severe COVID‐19, possibly via endothelial protective mechanisms.

prominent changes were detected in collagen fragments, specifically a reduction of collagen alpha-1(I) chain and collagen alpha-1(III) chain, and an increase in collagen alpha-2(I) chain fragments. In addition, a significant reduction of the abundance of CD99 antigen and polymeric immunoglobulin receptor and an increase in alpha-1-antitrypsin derived peptides were observed [4, 5] . Based on these differences, a signature comprised of 50 urinary peptides termed CoV50 was developed [4] , representing a molecular signature associated with disease severity [4] .

Due to the urgent need presented by the pandemic, an interim assessment of the study was initiated and recently published [4] . The data demonstrated that CoV50 enables prediction of COVID-19 severity, and consequently early intervention [4] . Based on the data, the A detailed investigation of the urine peptides significantly affected in patients that subsequently develop severe COVID-19 (defined here as World Health Organization [WHO] grade 6 or higher) indicated highly significant similarity to peptides altered in chronic and acute kidney disease [5] . The results also revealed that severe COVID-19 may be associated with endothelial damage, in agreement with the current literature [6] . As a consequence, therapy directed against SARS-CoV-2 may not deliver benefit if initiated at a later stage of the disease, when the endothelial layer is already damaged due to the virus infection. In fact, it has been shown that antiviral therapies display benefit only if initiated in the very early phases of SARS-CoV-2 infection [7, 8] . Thus, it is plausible that interventions targeting endothelial injury induced by the viral infection, and not the SARS-CoV-2 virus per se, may be beneficial in the treatment/prevention of severe COVID-19.

Drug repurposing has gained significant interest as a means to boost drug development. This is mainly attributed to the opportunity to decrease overall cost of drug development and timelines [9] . One computational (in silico) approach that has been used by multiple groups [10] including us [11, 12] , is prediction of drug efficacy based on the molecular signature of drug impact [13] . A well-established solution in this respect is the Connectivity Map (CMap) analysis [14] . In CMap, molecular disease signatures are matched against the transcriptomicbased molecular signatures induced by drug treatment in vitro.

In this study, our aim was to determine if drugs can impact the severe COVID-19 signature (CoV50). The study builds on what is known about the molecular signature associated with severe COVID-19, and was based on access to urinary peptide data from interventional studies involving patients without COVID-19. Such an analysis was feasible since urinary peptide data were obtained using the same technology, and are thus highly comparable [15] . The approach chosen here is the first attempt to use human-derived urinary peptide data for drug repurposing.

Power calculations indicated that in order to detect a 50% change in the CoV50 scoring with a p-value < 0.05 and 80% power, datasets from Here we report, for the first time, the application of clinical proteomics data, obtained from clinical trial participants, using a drug repurposing approach. The CoV50 signature was used to examine if molecular changes associated with COVID-19 severity in patients without COVID-19 might be altered using existing drugs. Empagliflozin demonstrated a partial, yet significant reversion of the CoV50 signature, indicating a potential benefit in severe COVID-19. a minimum of 17 subjects before and after treatment are required. We therefore only included studies involving at least 20 subjects. Investigation of the data in the urine proteome database [15] resulted in the identification and extraction of datasets from patients without COVID-19 undergoing treatment with the aldosterone antagonist spironolactone from the HOMAGE trial [16, 17] , and the sodium-glucose transport protein 2 (SGLT2)-inhibitor empagliflozin [18, 19] . As a part of the HOMAGE trial [16, 17] , the placebo group was also investigated. The details on the studies and the patient datasets included are listed in Table 1 .

The outline of this study is graphically depicted in Figure 1 . To identify a potential drug benefit in the context of COVID-19, ideally patients with COVID-19 receiving drug or placebo should be investigated. Unfortunately, such data are generally not available. As an alternative, the impact of drugs on the CoV50 signature can be investigated based on data from subjects without COVID-19 before and after drug treatment. Samples from these patients are expected to score negative for CoV50, since they did not have COVID-19. A change of the CoV50 score in the positive direction (towards severe COVID-19) would be considered as a signal for a potential negative effect of the drug. A change of the CoV50 score in the negative direction (reverting the CoV50 signature) indicates a potential benefit. and during follow-up (after treatment). The distribution of the CoV50 scoring in the baseline and follow-up samples is shown in Figure 2 .

While this was a study in a population without COVID- 19 [20] and anti-C5a antibodies [21] and polyclonal convalescent plasma [22] ), inflammation inhibitors [23] , small-molecule anti-virus therapies (remdesivir, lopinavir and ribavirin, hydroxychloroquine [8] ) and

steroids [24] in high and medium dosage schemes. Most of these drugs target the virus, and, as a result, are typically ineffective when applied at later stages of the disease. This indicates the urgent need for additional drugs that show efficacy at these stages. Several authors suggested that spironolactone may have potential positive impact in the context of COVID-19 [25] . Spironolactone, an aldosterone antagonist inhibiting the renin-angiotensin-aldosterone system (RAAS), is primarily used for management of heart failure, edematous conditions (nephrotic syndrome, ascites in cirrhotic adults), hypertension or hyperaldosteronism. Potential benefits from its use in COVID-19

patients were generally based on theoretical considerations. We could not identify a clinical trial testing a potential benefit of spironolactone.

In the BISCUIT trial a limited number of patients treated with bromohexine and spironolactone was compared to placebo, and a significant reduction on the duration of COVID-19 was reported [26] . However, in the small cohort of 33 patients, the fractional impact of any one of the two drugs apparently has not been assessed. Consequently, the impact of spironolactone treatment on COVID-19 cannot be evaluated with sufficient certainty. Our data presented here do not indicate a potential benefit of spironolactone.

COVID-19 including inflammation [27, 28] and endothelial dysfunction [29, 30] . These drugs are primarily used for the treatment of type 2 diabetes, with protective effects in cardiovascular and kidney diseases [31] . SGLT2 inhibitors were also recently approved for treatment of patients with heart failure and reduced ejection fraction, and for treatment of chronic kidney disease. The impact of SGLT2 inhibition on COVID-19 course was investigated in the DARE-19 study [32, 33] .

Treatment with dapagliflozin resulted in a lower number of events of organ dysfunction or death in comparison to placebo [33] . who were undergoing treatment with SGLT2 inhibitors or glucagon-like peptide-1 agonists [34] . Since this was a cohort study based on the data retrieved from national registries, an impact of these drugs could not be assessed in comparison to the placebo group.

Potential benefits of SGLT2 inhibitors in severe COVID-19 are further supported by reports from animal studies on protective effects of SGLT2 inhibition in the context of endothelial dysfunction [30] . Since a major component of severe COVID-19 appears to be endothelial dysfunction, drugs that demonstrate protective effects in this context may display benefits in preventing/reducing severe COVID-19.

Several observational studies reported on the repurposing of established drugs like aspirin [35] and statins [36] it is expected that development of drugs able to reverse the molecular signature, rather than focusing on a single target, will deliver more effective therapeutics. The observed significant decrease of the CoV50 score following treatment suggests that SGLT2 inhibitors may confer some protection from severe COVID-19 course. A significant impact of SGLT2 inhibition on the course of COVID-19 would need to be demonstrated in a properly powered prospective clinical trial.

In conclusion, the study and data presented here are a first indication that proteomics data from clinical trial participants can be exploited in a drug repurposing approach. A substantial benefit of the approach shown here may be that it is based on patient data, not on cell lines or animal models, and consequently may better depict pathophysiology in patients, which are by far more complex than single cells.

For this study urinary proteome data obtained by capillary electrophoresis coupled to mass spectrometry (CE-MS) and stored in the human urine proteome database [15] were assessed. This database currently contains urinary proteome/peptidome information on >80,000 samples, assessing a dataspace comprised total of >100,000 peptides and low molecular weight proteins [15] . were deconvoluted into single masses using MosaFinder software [4] .

Only signals with charge>1 observed in a minimum of three consecutive spectra with a signal-to-noise ratio of at least four were considered. The generated peak list included polypeptides characterised by mass and migration time. Mass and migration time were calibrated using internal standards by applying global and local linear regression, respectively [4] . Signals of 29 abundant peptides derived from collagens, generally not affected by disease, were used as internal standards for calibration of signal intensity using linear regression. This procedure was shown to be an easy and reliable method to address both analytical and dilution variances in a single calibration step [38] .

The final peak list was comprised of polypeptides described by its calibrated molecular mass (Da), calibrated CE migration time (min) and normalized signal intensity. More detailed information on the peptide sequencing was described elsewhere [39] . All underlying studies were consented to the study, which was approved by the University of Toronto University Health Network with approval #11-0213 [19] .

All samples from subjects undergoing spironolactone treatment and placebo controls were from the HOMAGE trial, a prospective, randomized, open-label, blinded-endpoint, multicentre design, in which people at increased risk of developing HF were randomly assigned to receive either spironolactone or standard of care ("control")-not receiving spironolactone or other mineralocorticoid receptor antagonists (Clini-calTrials.gov identifier: NCT02556450). The study was approved by all relevant ethics committees and regulatory bodies [17] .

Distribution of the CoV50 scoring was evaluated using MedCalc (version 12.1.0.0, MedCalc Software, Mariakerke, Belgium; https:// www.medcalc.org/). For analysis of differences in the scoring between baseline and drug treatment, paired T testing was applied, statistical significance was assumed at p < 0.05.

The study was supported by the German Federal Ministry of Health acting upon a decree from the German Federal Parliament.

Harald Mischak is the founder and co-owner of Mosaiques Diagnostics (Hannover, Germany). Agnieszka Latosinska and Justyna Siwy are employed by Mosaiques Diagnostics.

The CE-MS raw data are available on Zenodo: https://doi.org/10.5281/ zenodo.5464140.

Agnieszka Latosinska https://orcid.org/0000-0001-8917-2412

Clinical characteristics of coronavirus disease 2019 in China

Factors associated with COVID-19-related death using OpenSAFELY

Urinary proteomics associates with COVID-19 Severity: Pilot proof-of-principle data and design of a multicentric diagnostic study

CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology?

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, openlabel, platform trial

Repurposed antiviral drugs for COVID-19-Interim WHO solidarity trial tesults

Drug repurposing: Progress, challenges and recommendations

A review of connectivity map and computational approaches in pharmacogenomics

A novel pipeline for drug repurposing for bladder cancer based on patients' omics signatures

Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment

Drug repurposing in oncology

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future

Spironolactone effect on the blood pressure of patients at risk of developing heart failure: An analysis from the HOMAGE trial

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): An exploratory, open-label, phase 2 randomised controlled trial

A randomized trial of convalescent plasma in COVID-19 severe pneumonia

Tocilizumab in patients with moderate or severe COVID-19: A randomized, controlled, open-label, multicenter trial

Dexamethasone in hospitalized patients with COVID-19

COVID-19-the potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection

Results of open-label non-randomized comparative clinical trial: Bromhexine and spironolactone for coronаvirus infection requiring hospitalization (biscuiT)

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Empagliflozin suppresses inflammation and protects against acute septic renal injury

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study

Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: A systematic review of preclinical studies

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis

Impact of prior statin use on clinical outcomes in COVID-19 patients: Data from tertiary referral hospitals during COVID-19 pandemic in Italy

Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience

Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease

SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing